Hye Seon Kang1, Ah Young Shin2, Chang Dong Yeo3, Sung Kyoung Kim4, Chan Kwon Park5, Ju Sang Kim2, Seung Joon Kim6, Sang Haak Lee3, Jin Woo Kim7. 1. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 2. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 3. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 4. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 5. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 6. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 7. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea medkjw@catholic.ac.kr.
Abstract
BACKGROUND/AIM: Little is known about the prognostic role of the Glasgow prognostic score (GPS) in non-small cell lung cancer (NSCLC) patients treated with immunotherapy after platinum-based cytotoxic chemotherapy. PATIENTS AND METHODS: This study used a lung cancer cohort of the Catholic Medical Center of Korea between January 2018 and September 2020. RESULTS: A total of 78 patients with NSCLC treated with immunotherapy as second or further-line therapy were included. Higher GPS values were significant predictors of shorter immune-related progression-free survival (irPFS) and overall survival (OS). The hazard ratios for irPFS were 0.249 for programmed death-ligand 1 (PD-L1) expression ≥50% and 9.73 for a GPS of 2. Older age, lower PD-L1 expression and higher GPS values were independently associated with shorter OS. CONCLUSION: Higher GPS values were identified as a poor prognostic factor for OS and irPFS in NSCLC patients who received immunotherapy as second or further-line therapy.
BACKGROUND/AIM: Little is known about the prognostic role of the Glasgow prognostic score (GPS) in non-small cell lung cancer (NSCLC) patients treated with immunotherapy after platinum-based cytotoxic chemotherapy. PATIENTS AND METHODS: This study used a lung cancer cohort of the Catholic Medical Center of Korea between January 2018 and September 2020. RESULTS: A total of 78 patients with NSCLC treated with immunotherapy as second or further-line therapy were included. Higher GPS values were significant predictors of shorter immune-related progression-free survival (irPFS) and overall survival (OS). The hazard ratios for irPFS were 0.249 for programmed death-ligand 1 (PD-L1) expression ≥50% and 9.73 for a GPS of 2. Older age, lower PD-L1 expression and higher GPS values were independently associated with shorter OS. CONCLUSION: Higher GPS values were identified as a poor prognostic factor for OS and irPFS in NSCLC patients who received immunotherapy as second or further-line therapy.
Authors: Claribel P L Simmons; Donald C McMillan; Kerry McWilliams; Tonje A Sande; Kenneth C Fearon; Sharon Tuck; Marie T Fallon; Barry J Laird Journal: J Pain Symptom Manage Date: 2017-01-04 Impact factor: 3.612
Authors: Joerg Lindenmann; Nicole Fink-Neuboeck; Valentin Taucher; Martin Pichler; Florian Posch; Luka Brcic; Elisabeth Smolle; Stephan Koter; Josef Smolle; Freyja Maria Smolle-Juettner Journal: Cancers (Basel) Date: 2020-01-08 Impact factor: 6.639